Maria Jarecka, Piotr Borowicz

Bewacizumab - przeciwciało monoklinalne w terapii celowanej zaawansowanego raka jelita grubego

Bevacizumab - monoclonal antibody in the targeted therapy of advanced colorectal cancer. Colorectal cancer is one of the most common cancers worldwide, including Poland. Over the past few years, the introduction of new systemic therapies and integration of biologically targeted agents with cytotoxic chemotherapy has significantly improved the median survival for patients with advanced, metastatic colorectal cancer. Bevacizumab is a humanized recombinant monoclonal antibody that inhibits the biological activities of vascular endothelial growth factor (VEGF). In patients receiving an irinotecan plus fluorouracil/leucovorin (IFL) regimen for first-line treatment of metastatic colorectal cancer, the addition of bevacizumab significantly increased overall survival by 4.7 months relative to IFL plus placebo. In the second-line treatment of advanced colorectal cancer, patients who received bevacizumab in combination with a fluorouracil/leucovorin plus oxaliplatin (FOLFOX4) regimen had an overall survival time 2 months longer than that in patients receiving FOLFOX4. Bevacizumab has acceptable tolerability in patients with advanced colorectal cancer, with the majority of adverse events being generally mild to moderate and clinically manageable. Thus bevacizumab provides a highly effective addition to standard chemotherapeutic regimens for advanced metastatic colorectal cancer.